ClinicalTrials.gg
Active, not recruitingNCT04365790Updated Oct 14, 2026

Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma

An observational study in Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Active, not recruiting at 1 site in Greece. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hellenic Cooperative Oncology Group · Observational

How we know

Updated Oct 14, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.

Enrollment
6th of 14
500 · median 423
Started
2013
with 1 other
Observational
14 of 18
3 open now
Registered
7th of 18
by date

Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 6th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2013, is one of 14 observational ones, and was the 7th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, or all of them as a file.
02

Study summary

The present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel or paclitaxel.

Read the detailed description

This will be a retrospective analysis of patients with histologically confirmed triple-negative or HER2+ operable breast cancer (with high risk of recurrence) who are treated at Hellenic Cooperative Oncology Group (HeCOG)- affiliated departments of oncology. Patients who participate are 18 years or older, women of any menopausal status with triple-negative or HER2+ breast cancer who receive epirubicin and cyclophosphamide every two weeks followed by docetaxel every three weeks or weekly paclitaxel. Patients with HER2-positive tumors are treated with trastuzumab, initiated concurrently with the first cycle of docetaxel, for 52 weeks. Pertuzumab may be combined with trastuzumab only in patients with node-positive disease.Patients can be treated with hormone therapy and/or radiotherapy. The investigation of the potential biomarkers will be performed using in situ methods in Formalin fixed paraffin embedded (FFPE) tumor sections. More specific will be investigated the expression of estrogen and progesterone receptors, the expression of SPARC proteins, special cellular activation and metastasis systems and other important pathways in cell life and reproduction.

Statistical analysis: The primary endpoint of the study will be the progression-free survival (PFS), defined as the time from treatment initiation to either the first documented disease progression or death from any cause. Second primary endpoint will be the overall survival (OS), defined as the time from treatment initiation to patient's death or last contact. Survival curves will be estimated using the Kaplan-Meier method and compared across groups with the log-rank test. The associations between the clinicopathological factors to be examined and the mortality rate will be evaluated with hazard ratios estimated with Cox proportional hazards model. The statistical analyses will be completed using the SAS software (SAS for Windows, version 9.3, SAS Institute Inc., Cary, NC).

03

Conditions studied

  • Breast Cancer

Keywords

  • Triple-negative breast cancer
  • HER2 positive breast adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is a retrospective analysis of patients with histologically confirmed HER2- positive breast adenocarcinoma,triple-negative breast cancer with high risk of recurrence.

Patients have been treated in Hellenic Cooperative Oncology Group (HeCOG)- affiliated departments of oncology.

Eligibility criteria

Inclusion Criteria:

  • 18 years or older
  • Αny menopausal status is allowed
  • triple-negative breast cancer
  • + breast adenocarcinoma
  • tumor size \<= 5 cm
  • presence of operable axillary lymph nodes or the presence of clinicopathological parameters indicating an intermediate or high risk of recurrence without the presence of infiltrated lymph nodes
  • Performance status (PS) = 0 or 1
  • adequate bone marrow function , heart, liver and kidney
  • no other history of previous neoplasm or other serious illness

Exclusion Criteria: -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with triple-negative breast cancer

    Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology

  • Patients with HER2+ positive breast cancer

    Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: From treatment initiation to the first documented disease progression, up to 5 years

  2. Overall survival

    Time frame: from thee date of treatment initiation until death from any cause or date of last contact whichever occurred first, assessed up to 5 years

07

Study locations

1 site
  • George Fountzilas
    Athens, Greece
08

References and documents

Publications

  • Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6 Suppl 3:30-5. doi: 10.1634/theoncologist.6-suppl_3-30. PubMed 11346683 ↗
  • Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983 Nov 1;52(9):1551-7. doi: 10.1002/1097-0142(19831101)52:93.0.co;2-3. PubMed 6352003 ↗
  • Nissen-Meyer R, Kjellgren K, Mansson B. Adjuvant chemotherapy in breast cancer. Recent Results Cancer Res. 1982;80:142-8. doi: 10.1007/978-3-642-81685-7_24. PubMed 7036276 ↗
  • Meyer JS, McDivitt RW, Stone KR, Prey MU, Bauer WC. Practical breast carcinoma cell kinetics: review and update. Breast Cancer Res Treat. 1984;4(2):79-88. doi: 10.1007/BF01806389. PubMed 6378283 ↗
  • Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998 Jul;4(7):844-7. doi: 10.1038/nm0798-844. PubMed 9662379 ↗
  • Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):1-6. doi: 10.1097/00129039-200203000-00001. PubMed 11893029 ↗
  • Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000 Dec;80(12):1943-9. doi: 10.1038/labinvest.3780204. PubMed 11140706 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2013 to primary completion in Jul 2026, 158 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2020 → Jul 2026 and completion Sep 2023 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 28, 2020
StartActual
Apr 18, 2013
Primary completionActual
Jul 13, 2026was Dec 2020
CompletionEst.
Feb 2027was Sep 2023
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Oct 14, 2026
Primary completion
Dec 21, 2020→Jul 13, 2026
Oct 14, 2026
Study completion
Sep 2023→Feb 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Status unknown→Active, not recruiting
    Primary completion Dec 21, 2020→Jul 13, 2026
    Study completion Sep 2023→Feb 2027
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04365790
Lead sponsor
Hellenic Cooperative Oncology Group
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
Apr 18, 2013
Primary completion
Jul 13, 2026
Completion
Feb 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

George Foutzilas, MD
principal investigator · Hellenic Cooperative Oncology Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion